ASCO GU 2023

New updates on immunocheckpoint inhibitors and ADCs - which therapy for which patient?

Robust DFS benefit, but lack of OS data leaves open questions

Bladder preservation strategies - promising data but no change in SoC yet?!

Final overall survival

Re-shaping bladder cancer treatment

Benefit of neoadjuvant pembro for CE and CI patients

No change in SoC, but new genomic predictors for EV outcome

Pembro for HR NMIBC

IMvigor130: final OS

PD-1 as combo in 1st line

Urothelial cancer highlights from ASCO GU23

Atezo monotherapy for mUC

No final OS difference - but subgroups may benefit from Atezolizumab

Final OS data show no significant benefit for chemo plus ICI

Update / German Real World Data M1 BC

3 yrs outcome of Nivo for adjuvant therapy

The bladder cancer highlights of ASCO GU

NMIBC highlights from ASCO GU23

Urothelial cancer - hidden gems of the poster session

Impressive DFS with adjuvant Nivo in biomarker-positive patients

Checkpoint inhibition in adjuvant therapy

Exciting survival data for adjuvant NIVO

New data for pembro in HR NIMBC

Pembrolizumab in HR NIMBC

PARPi are effective in PCa - which subgroups benefits most?

Επισημάνσεις για τον καρκίνο του ουροθηλίου από την ASCO GU23

Refinando el tratamiento del cancere vejiga

Los aspectos más destacados del ASCO GU 2023 en cáncer de vejiga

BCG yanıtsız yüksek riskli KİOMK tedavisinde Pembrolizumab

The bladder cancer highlights of ASCO GU

Benefits and risks of precision medicine with PARPi

BRCA mutations in mCRPC - the importance of biomarkers in PCa! Why we need better testing and better understanding of therapy combinations!

Triplet combination - all-comer therapy or high risk high volume only? How do we identify the patients who benefit?

Monotherapy is not any longer standard of care

Normal baseline testosterone level is a strong predictor of post-ADT recovery

mHSPC - new standard and more insights

ARASENS - post-hoc subgroup analysis

Benefit in all groups

Formula 509: Racing to a better straegy for radiotherapy

Controversy in ADT roundtable

New ways to target androgen receptor signaling

PARP and testing

MMAI - a superior prognostic marker for high risk patients

Intensification of salvage therapy in high risk settings

ARASENS: triple independent of volume and risk

Doublet or all-in: the solution for all patients?

Surgery vs. Radiation for N1 PCa: who wins?

PARPi study with different design

Rucaparib: treatment option for biomarker-selected patients

Rucaparib - ready for clinical practice in BRCAmut patients

PARPi are effective in PCa - which subgroup benefits most?

PARPi & ARPi with wonderful data

PARPi combo: all-comer treatment for mCRPC

Rucaparib - the new player?

PARPi combo approval for all-comers - balancing benefit of treamtent vs. side effects is crucial

Tiebreaker for previous trials

Propel - final OS

Encouraging results for Talazoparib

TALA ENZO with improved PFS in mCRPC

TALA in 1st line for all patients with mCRPC

PARPi combination in mCRPC

Ny PARP hämmar studie med anna design

Lokalize prostat kanserinde cerrahi ile SBRT karşılaştıran faz-3 randomize kontrollü çalışma

edavi öncesi normal testosteron seviyesi ADT sonrası testosteron geri dönüşü için güçlü bir prediktördür

MMAI- Yüksek riskli prostat kanserinde üstün bir prognostik belirteç

Nya vägar att blockera androgenreceptor signalering

TALA ENZA kombinasyonu ile mKDPK olan hastalarda daha iyi progresyonsuz sağkalım

miR371'in orşiektomi sonrası tedavi seçimini yönlendirmekteki yüksek doğruluğu

PARPi & ARPi με υπέροχα δεδομένα

RP sonrası kurtarma RT ile GnRH Analog ABİ APA kombinasyonu, kurtarma RT ve GnRH analog tedavisinden daha iyi PFS sağlar mı?

Novel updates on cabozantinib in advance RCC

Theranostics in RCC - usefull tools for ccRCC?!

Updated data of CheckMate 9ER - impact on real-world therapy

New therapy choices for renal cell cancer patients

Reassuring update of CM9ER with longer follow up

Longer FU confirms significant benefit of Nivo-Cabo, Cabo effective post IO first line

First prospective data on 2nd line therapy after IO combination in mRCC

Zircon-PET in RCC

Outcomes of patients with brain metastases treated with first-line therapies

Hypothesis-generating differences in risks groups

Refining prediction of stage I seminoma

High accuracy of miR371 to guide treatment selection after orchiectomy

microbiom & CPI perspectives

Mejorando la estimacion pronostica en Seminoma Estadio I